Navigation Links
Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
Date:3/1/2010

NEW YORK, March 1 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has named Michael D. Dellario, 57, to the newly-created position of Vice President, Global Marketing, effective today. Mr. Dellario will report to Agustin Gago, EVP, Global Sales and Marketing.

"The new position of Vice President, Global Marketing is a critical component as we build our domestic and international commercialization team in anticipation of FDA approval and CE designation for the Delcath PHP System™," said Mr. Gago. "Michael's record of success in bringing innovative medical products to worldwide markets gives us confidence that he will have a significant impact on the commercialization of the Delcath PHP System as we continue to implement our plans in key European and Asian markets."

Mr. Dellario was most recently a marketing consultant for startup medical companies in the early stages of marketing development, providing marketing strategies and commercialization support. Prior to that, Mr. Dellario was Managing Director, Asian Operations at E-Z-EM/Bracco Inc., a medical equipment and software, devices and diagnostic pharmaceuticals company, from 2006 to 2008. There, he designed a focused marketing program and channel distribution plan that grew Asian business by 78%. Before that, he was Vice President of Marketing at Ekos Corp., Inc., an interventional devices and equipment startup focusing on therapeutic ultrasound.

From 1992 to 2005, Mr. Dellario held several marketing positions at AngioDynamics, Inc. Prior to that, he held sales and marketing positions for medical technology companies. Mr. Dellario received his MBA from Lidenwood University and his BS from St. Louis University, both in St. Louis, Missouri.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of primary and metastatic liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer agents to the liver while controlling the systemic exposure of those agents.  In addition to its fully enrolled Phase III metastatic melanoma study, the Company is currently conducting trials to treat other forms of tumor metastases to the liver. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.

Back to top

RELATED LINKS
http://www.delcath.com

'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
2. Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
3. Delcath Enters Agreement to Sell 869,565 Units
4. Delcath Systems Granted Third Orphan Drug Designation
5. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
7. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
8. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
9. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
10. New Online Tutorials for NCBI resources BioSystems and DCODE
11. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... This report analyzes the worldwide markets for Biostimulants ... Amino, & Fulvic), Extract Based, and Others. The report also ... & Turf, Row Crops, and Others. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and forecasts are ...
(Date:12/8/2016)... 8, 2016  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... intratumoral cancer immunotherapies, today announced financial results for ... "We are delivering on our commitment to address ... IL-12. We are pleased with the early clinical ... and we are focused on advancing our lead ...
(Date:12/8/2016)... PUNE, India , December 8, 2016 ... is a comprehensive analysis, titled Global Amyloglucosidase Industry 2016 Market ... definition, classification, application, and industry chain overview are all covered ... project SWOT analysis, and investment return analysis of the Amyloglucosidase ... , , ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and type 2 ... license for a novel adeno-associated virus (AAV) vector ... Kay , M.D., Ph.D., at Stanford University. The ... of its paracrine gene therapy product pipeline. ...
Breaking Biology Technology:
(Date:11/22/2016)... , November 22, 2016 According to the new ... Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function ... by MarketsandMarkets, the market is expected to grow from USD 10.74 Billion ... of 16.79% between 2016 and 2022. Continue ... ...
(Date:11/17/2016)... -- AIC announces that it has just released a new white paper authored by Zettar ... high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
Breaking Biology News(10 mins):